Title
Society of Family Planning Committee statement on IUD nomenclature

Permalink
https://escholarship.org/uc/item/72z7w4q4

Authors
Creinin, Mitchell
Kohn, Julia E
Tang, Jennifer H
et al.

Publication Date
2022-02-01

DOI
10.1016/j.contraception.2021.10.017

Peer reviewed
Commentary

Society of Family Planning Committee statement on IUD nomenclature

Mitchell Creinin\textsuperscript{a,}*, Julia E. Kohn\textsuperscript{b}, Jennifer H. Tang\textsuperscript{c}, Tania Basu Serna\textsuperscript{d}, on behalf of the Society of Family Planning Clinical Affairs Committee\textsuperscript{f}

\textsuperscript{a}Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, United States
\textsuperscript{b}Planned Parenthood of Northern, Central and Southern New Jersey, Morristown, NJ, United States
\textsuperscript{c}Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
\textsuperscript{d}Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, CA, United States

A R T I C L E   I N F O

Article history:
Received 14 July 2021
Received in revised form 6 October 2021
Accepted 10 October 2021

Keywords:
intrauterine device
IUD
hormonal
non-hormonal
copper
levonorgestrel

1. Introduction

Recently, the World Health Organization (WHO) released a statement regarding intrauterine device (IUD) nomenclature to clarify various terms used for intrauterine contraception [1]. This clarification was prompted, according to the statement, because “(t)he use of many different acronyms to describe a method category can lead to confusion among governments, procurers, distributors, academics, providers and users.” The WHO added that “(i)t is important to select and align a single term.”

The Society of Family Planning fully agrees with this reasoning to move forward with clarifying terminology related to intrauterine contraceptives. While, historically, these contraceptives had always been referred to as IUDs, the pharmaceutical industry introduced the term “intrauterine system” and the abbreviation “IUS” as a means of differentiating levonorgestrel from copper devices in marketing and promotional materials.

As we have learned from misunderstandings related to combined oral contraceptive “generations,” attempts by pharmaceutical companies to create new product types for market differentiation simply leads to confusion [2], as the WHO appropriately summarizes.

The WHO statement dictates that IUDs be categorized as non-hormonal IUDs and hormonal IUDs. The WHO further defines terminology within these categories, stating that nonhormonal IUDs should be called copper-bearing IUDs and hormonal IUDs should be called “hormone”-releasing IUDs, identified by the type of hormone (e.g., levonorgestrel-releasing IUD). The WHO stresses the importance of naming the hormone to ensure that patients and providers are aware that the IUD releases a hormone, and that the product does not contain estrogen.

The Society of Family Planning applauds the WHO for its efforts and agrees with the conclusion that any intrauterine contraceptive should be referred to as an intrauterine device (IUD), and that IUDs should be categorized as nonhormonal IUDs and hormonal IUDs. The WHO issued this statement to name categories in line with their common approach to nomenclature for a broad global audience. The Society feels the nomenclature needs additional detail to be appropriate for more potential audiences like researchers, authors, and pharmaceutical companies, and makes the following recommendations.

\textsuperscript{a} Corresponding author. M.D. Creinin.
\textsuperscript{f} This commentary was authored by Mitchell D. Creinin, MD on behalf of the Society of Family Planning Clinical Affairs Committee in collaboration with Julia E. Kohn, PhD, MPH, Jennifer H. Tang, MD, MSCR, and Tania Basu Serna, MD, MPH. The Board of the Society of Family Planning reviewed and approved the document. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of Planned Parenthood Federation of America, Inc.

https://doi.org/10.1016/j.contraception.2021.10.017
0010-7824/© 2021 Elsevier Inc. All rights reserved.
2. Recommendations

1. The IUD should be referred to as the hormone (e.g., levonorgestrel) or copper with the dose included to help patients and providers differentiate the products.

The Society recommends matching terminology for IUDs like other hormonal contraceptive drugs or devices by not including the terms “releasing” or “bearing.” For example, implants are not labeled as hormone-releasing implants, but simply etonogestrel or levonorgestrel implants. Of note, copper is released from the IUD as it elutes in the intrauterine environment. The WHO proposed terminology of copper-bearing IUD implies that the copper is stagnant on the IUD and is not released.

2. The nomenclature should account for doses in both hormonal and nonhormonal IUDs.

Currently available levonorgestrel IUDs come in different doses with different release rates. Importantly, the same issue exists for copper IUDs, with ranges from 200 to 380 mm² doses, based on surface area. Note that a new copper IUD, currently in phase 3 studies, has only 175 mm² of exposed copper [3], so differentiating dose is important.

3. IUD types and doses in publications and communications should be written according to standard medical practice.

Many providers are not used to writing prescriptions because medications and devices are commonly ordered through electronic medical record systems. How we talk about a drug or device is not how we write the same information. Clinicians correctly write medications as NAME DOSE followed by instructions for use, including ROUTE [4]. Nothing about the dose relates to a release rate but, rather, the amount and units present in or on the product.

Based on these recommendations, currently available products in the United States would include (Fig. 1):

- Copper 380 mm² IUD
- Levonorgestrel 13.5 mg IUD
- Levonorgestrel 19.5 mg IUD
- Levonorgestrel 52 mg IUD

The Society of Family Planning recognizes that names alone are sometimes not enough to explain the product in totality; other features, including the type of frame, may also be necessary to fully differentiate products. Accordingly, the Society endorses that clinicians remain well educated about the different options so as to provide the best counseling for patients.

This Committee Statement will be used as guidance for IUD terminology in all Society of Family Planning publications. The Society cannot control others’ text but can only create guidance. Accordingly, the Society hopes this recommended IUD nomenclature will be referenced as a standard by clinicians, researchers, pharmaceutical companies, other national and international organizations, and agencies such as the U.S. Food and Drug Administration.

3. Future considerations

Reference to IUD frame shape or form are not part of the WHO or Society of Family Planning recommendations. Currently available IUDs in most of the world are “T-shaped,” although some rings and omega-shaped IUDs exist in China. Importantly, not all T-shaped IUDs are the same T. The Copper T380A, for example, is a “Tatum-T” which is a true T-shape. Hormonal IUDs and some copper IUDs are actually a Nova-T, in which there is no perpendicular meeting of the arm and stem. Rather, the stem diverges at the top to curve into each of the arms, forming a small “V” which allows the arms to easily fold upward. The new lower dose copper IUD uses a T-shaped nickel titanium frame [3]. Lastly, a multiload frame is a “shaped” frame with 2 arms that bend downward from the stem, like wings, with small outward facing spikes, which is different from a “T” shape. The Society of Family Planning notes that, as shape and form continue to evolve, future nomenclature will need to include these differentiators as well.

Declaration of Competing Interest

Mitchell D. Creinin has received speaking honorarium from Gedeon Richter, serves on an Advisory Board for Evofem and Merck, and is a consultant for Danco, Estetra, Mayne, Medicines360, and Merck. The Department of Obstetrics and Gynecology, University of California, Davis, receives contraceptive research funding for Dr. Creinin from Chemo Research SL, Evofem, HRA Pharma, Medicines360, Merck, and Sebela. All other authors report no conflicts of interest.

References